Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-04-05 4:15 pm Sale |
2024-04-03 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund V L.P. | 0 0.000% |
-13,779,062 (Position Closed) |
Filing History |
| 2024-02-22 4:39 pm Unchanged |
2024-02-16 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund V L.P. | 13,779,062 29.200% |
0 (Unchanged) |
Filing History |
| 2024-02-05 3:15 pm Purchase |
2024-01-24 | 13G | CG Oncology, Inc. Common stock CGON |
Foresite Capital Fund V L.P. | 3,595,203 5.700% |
3,595,203 (New Position) |
Filing History |
| 2023-11-24 4:23 pm Unchanged |
2023-11-22 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 5,494,621 12.400% |
0 (Unchanged) |
Filing History |
| 2023-11-17 08:00 am Unchanged |
2023-11-17 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund V L.P. | 13,779,062 29.200% |
0 (Unchanged) |
Filing History |
| 2023-11-14 4:30 pm Purchase |
2023-11-13 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund V L.P. | 13,779,062 29.200% |
13,779,062 (New Position) |
Filing History |
| 2023-07-19 2:41 pm Purchase |
2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 5,494,621 12.600% |
700,000 (+14.60%) |
Filing History |
| 2023-02-13 5:20 pm Purchase |
2022-12-31 | 13G | Compass Therapeutics, Inc. CMPX |
Foresite Capital Fund V L.P. | 5,954,250 4.700% |
454,250 (+8.26%) |
Filing History |
| 2023-01-03 4:36 pm Purchase |
2022-12-29 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 4,794,621 12.400% |
500,000 (+11.64%) |
Filing History |
| 2022-06-13 4:24 pm Purchase |
2022-06-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 4,294,621 11.100% |
613,069 (+16.65%) |
Filing History |
| 2022-02-11 3:08 pm Sale |
2021-12-31 | 13G | POPULATION HEALTH INVT CO INC PHICU |
Foresite Capital Fund V L.P. | 0 0.000% |
-1,200,000 (Position Closed) |
Filing History |
| 2022-02-11 3:07 pm Unchanged |
2021-12-31 | 13G | LifeSci Acquisition II Corp. LSAQ |
Foresite Capital Fund V L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-02-11 3:05 pm Sale |
2021-12-31 | 13G | Cullinan Oncology, Inc. CGEM |
Foresite Capital Fund V L.P. | 1,524,008 3.500% |
-2,117,871 (-58.15%) |
Filing History |
| 2021-11-12 06:10 am Purchase |
2021-11-02 | 13G | Compass Therapeutics, Inc. CMPX |
Foresite Capital Fund V L.P. | 5,500,000 5.600% |
5,500,000 (New Position) |
Filing History |
| 2021-10-18 1:15 pm Purchase |
2021-10-07 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 3,681,552 9.800% |
3,681,552 (New Position) |
Filing History |
| 2021-01-15 06:05 am Purchase |
2021-01-08 | 13G | Cullinan Oncology, Inc. CGEM |
Foresite Capital Fund V L.P. | 3,641,879 8.800% |
3,641,879 (New Position) |
Filing History |
| 2020-11-25 06:03 am Purchase |
2020-11-18 | 13G | POPULATION HEALTH INVT CO INC PHICU |
Foresite Capital Fund V L.P. | 1,200,000 7.000% |
1,200,000 (New Position) |
Filing History |
| 2020-11-25 06:01 am Purchase |
2020-11-20 | 13G | LifeSci Acquisition II Corp. LSAQ |
Foresite Capital Fund V L.P. | 500,000 6.700% |
500,000 (New Position) |
Filing History |